Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
Bio-Bridge Science, Inc. (OTCBB:BGES),
a biotechnology company engaged in the commercial development of
vaccines for the prevention and treatment of human infectious diseases
issues a corporate update today.
The Company’s strategy is to develop its own
vaccines, to establish a vaccine and drug distribution network, and to
acquire promising vaccine-producing and vaccine-related companies in
China to diversify product offerings.
Complementary Acquisition
The Company is in discussions with several potential acquisition targets
in China. These targets are primarily vaccine companies with increasing
vaccine sales and stable sales channels. Other targets include vaccine
development and production-related companies. Our short-term goal is to
acquire one of these vaccine companies, which will increase our product
offerings and revenues, and establish our first sales channel in China.
Our goal is to acquire at least 51% of a target company at a reasonable
price. We will provide further information when an acquisition agreement
has been signed.
In-House Vaccine Product Development
HIV vaccine: The pre-clinical studies of our HIV Vaccine on laboratory
animals were completed by the Beijing Institute of Radiation Medicine
and showed encouraging results. After the vaccine samples are produced
in our GMP facility in Beijing, we will submit application for clinical
trials with the SFDA.
Second generation of a HPV vaccine (a polyvalent vaccine): We entered
into a cooperative agreement with the Institute of Basic Medical
Sciences at the Chinese Academy of Medical Sciences, a leading medical
research institute in China, to research and develop a human
papillomavirus polyvalent vaccine using prokaryotic expression system
(HPV vaccine). This vaccine is designed to prevent from infection by
human papillomavirus types 6, 11, 16, 18, 31, 45, and 58 and would, if
successful, prevent more types of HPV infection than the current
vaccines in the market and the cost of the production will be
significantly lower. Currently the pre-clinical study of the HPV vaccine
is under way. We expect that the pre-clinical study can be completed in
the second half of 2008.
Facility Completion Update
The electricity project for our GMP facility in Beijing is in process
and the Company expects the project to be completed in the second half
of 2007. We expect at that time the facility will be fully operational.
Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We believe
that a completion of our planned acquisition will enable us to increase
our revenue and build a vaccine and drug distribution network in China.
Also, our association with leading medical research institutes in China
will solidify our research capability as we try to introduce more
potential vaccine products in addition to our current vaccines in
development.”
This press release contains forward-looking statements. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including, but
not limited to, product and service demand and acceptance, changes in
technology, economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are expressly
qualified by these cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after the
date hereof. Please refer to the Company’s SEC
filings for additional information.